TSX lower as gold rally takes a breather
BURLINGTON, N.C. - Labcorp Holdings Inc. (NYSE:LH), currently trading near its 52-week high at $277.51 and maintaining a market capitalization of $23 billion, announced Wednesday that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock, representing an annual yield of 1.03%.
The dividend will be paid on December 11, 2025, to stockholders of record as of the close of business on November 26, 2025, according to a press release statement from the company. According to InvestingPro data, the company demonstrates strong financial health with consistently low price volatility.
Labcorp, a provider of laboratory services to healthcare providers, pharmaceutical companies, and researchers, operates in approximately 100 countries with a workforce of nearly 70,000 employees.
The company performs more than 700 million tests annually for patients worldwide and supported more than 75% of the new drugs and therapeutic products approved by the FDA in 2024.
In other recent news, Labcorp has completed its acquisition of select assets from BioReference Health, a subsidiary of OPKO Health, in a deal valued at up to $225 million. This acquisition includes laboratory testing businesses focused on oncology across the United States, with Labcorp paying $192.5 million at closing and an additional $32.5 million potentially based on performance. Additionally, Labcorp has launched the first FDA-cleared blood test for Alzheimer’s disease, the Lumipulse pTau-217/Beta Amyloid 42 Ratio, which offers a less invasive diagnostic alternative.
In collaboration with Roche, Labcorp is set to implement FDA-cleared digital pathology scanners, addressing the projected shortage of pathologists in the U.S. by 2030. Jefferies has raised its price target for Labcorp to $300, maintaining a Buy rating, following a 1% top-line beat in the company’s quarterly results. Evercore ISI also increased its price target to $300, citing strong diagnostic growth from both organic sources and acquisitions, while maintaining an Outperform rating. These developments highlight Labcorp’s strategic expansions and innovations in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.